Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
39.18
-1.87 (-4.56%)
Feb 21, 2025, 4:00 PM EST - Market closed
Veracyte Revenue
Veracyte had revenue of $115.86M in the quarter ending September 30, 2024, with 28.58% growth. This brings the company's revenue in the last twelve months to $425.33M, up 23.95% year-over-year. In the year 2023, Veracyte had annual revenue of $361.05M with 21.76% growth.
Revenue (ttm)
$425.33M
Revenue Growth
+23.95%
P/S Ratio
6.94
Revenue / Employee
$521,879
Employees
815
Market Cap
3.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 361.05M | 64.52M | 21.76% |
Dec 31, 2022 | 296.54M | 77.02M | 35.09% |
Dec 31, 2021 | 219.51M | 102.03M | 86.85% |
Dec 31, 2020 | 117.48M | -2.89M | -2.40% |
Dec 31, 2019 | 120.37M | 28.36M | 30.82% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VCYT News
- 3 days ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 8 days ago - New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - Business Wire
- 11 days ago - Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium - Business Wire
- 17 days ago - New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - Business Wire
- 18 days ago - Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025 - Business Wire
- 2 months ago - Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines - Business Wire
- 3 months ago - Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Veracyte Announces Third Quarter 2024 Financial Results - Business Wire